RELATED CONTENT
NEWS
- BMS' Yeryoy and Roche's Zelboraf get final NICE nod
- NICE U-turns on Roche's Zelboraf and BMS' Yervoy for advanced malignant melanoma
- Roche's RoActemra is better than Abbot's Humira, says Scotland, but Zelboraf fails to impress
- US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment

